anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Neonatal hypoxia-ischemia (HI) is one of the main causes of mortality and long-term disabilities in newborns, and the only clinical approach to treat this condition is therapeutic hypothermia, which shows some limitations. Thus, putative neuroprotective agents have been tested in animal models of HI. Lactate is a preferential metabolic substrate of the neonatal brain and has already been shown to produce beneficial neuroprotective outcomes in neonatal animals exposed to HI. Here, we administered lactate as a treatment in neonatal rats previously exposed to HI and evaluated the impact of this treatment in adulthood. Seven-day-old (P7) male and female Wistar rats underwent permanent common right carotid occlusion combined with an exposition to a hypoxic atmosphere (8% oxygen) for 60 min. Animals were assigned to one of four experimental groups: HI, HI+LAC, SHAM, SHAM+LAC. Lactate was administered intraperitoneally 30 min and 2 h after hypoxia in HI+LAC and SHAM+LAC groups, whereas HI and SHAM groups received vehicle. Animals were tested in the behavioral tasks of negative geotaxis and righting reflex (P8), cylinder test (P24), and the modified neurological severity score was calculated (P25). Open field (OF), and novel object recognition (NOR) were evaluated in adulthood. Animals were killed at P60, and the brains were harvested and processed to evaluate the volume of brain injury. Our results showed that lactate administration reduced the volume of brain lesion and improved sensorimotor and cognitive behaviors in neonatal, juvenile, and adult life in HI animals from both sexes. Thus, lactate administration might be considered as a potential neuroprotective strategy for the treatment of neonatal HI, which is a prevalent disorder affecting newborns.
The study is an international, multicenter, randomized controlled trial. 202 patients with a single level TL burst fracture will be enrolled in the study. They will be randomized 1:1 to either surgery with posterior fixation or non-surgical treatment. The study is pragmatical in its approach, i.e., the treating physician can decide on details of the surgical treatment as well as details of the non-surgical treatment. In non-surgically treated patients brace treatment is not required, but a hyperextension brace may be offered. The subjects will be followed with patient reported outcomes, clinical assessments, and radiological assessments. Data will be collected from questionnaires, patient files or national registers to compare sick leave, medical complications, pharmaceutical prescriptions and overall costs for each treatment.
A vaccine active against at least one of the following, namely Braxy in sheep, Black disease and Blackleg in sheep or cattle comprises an aqueous preparation including at least one of the following namely (A) at least 2.5 total combining units per ml. of preparation of toxoided toxin from a toxigenic strain of Clostridium septicum; (B) at least 5.0 flocculation equivalents per ml. of preparation of toxoided a -toxin from a toxigenic strain of Clostridium oedematiens type B and (C) at least 106 per ml. of preparation of killed cells of a toxigenic strain of Clostridium chauvoei, which cells may be partially or wholly replaced by an extract thereof, the preparation containing p  not more than 1.0 mg. total nitrogen or 1.0 mg. protein nitrogen per individual antigenic component of the vaccine.  The vaccine is prepared by culturing separately a toxigenic strain of Cl. chauvoei, Cl. septicum or Cl. oedematiens type B in a culture medium therefor; separating the cells from the culture medium; where required, toxoiding the toxin in the medium and ultrafiltering the medium to remove some of the water and medium ingredients; where required, killing the separated cells and, where required, extracting the whole or part of said cells; followed, where required, by blending the products so obtained to form a vaccine as above.  The blackleg vaccine is obtained by cultivating Cl. chauvoei in a nutrient medium containing enzymatic digest of meat at pH 7.6 to 7.8 at 37 DEG  C. under anaerobic conditions for 48 hours.  After centrifugation, the cells are killed by formalinisation (1%) for 7-10 days until sterile.  The medium is filtered and treated with 1% formalin at pH 7.4 and 37 DEG  C. for 5 to 6 days to form toxoid.  It is purified by (a) ultrafiltration through a collodion or cellulose membrane until the volume of the medium is reduced 50 times; (b) dialysis of the concentrated toxoided toxin against sodium acetate/acetic acid solution for 2 to 3 days and redissolving the precipitate so formed in a phosphate buffer at pH 6.5.  Both killed cells and the purified toxoided toxin may be separately absorbed on to a parenterally acceptable absorbent such as aluminium hydroxide gel and then mixed together to form a vaccine which may also contain isotonic sodium chloride and a preservative.  The braxy vaccine consists of a toxoid and lysate of cells of Cl. septicum.  The lysate being prepared by treating the cells with strong saline and dialysing to remove inorganic salts.  Braxy, Blackleg and Black Disease vaccines may be mixed, either singly or in combination, with preparations active against tetanus and/or Pulpy Kidney Disease in lambs.  Specification 901,433 is referred to.
The invention is directed to 6-(4-py??midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
BACKGROUND: Characteristics of children with impaired development who have acute appendicitis are not well described in the literature.
METHODS: We reviewed the National Surgical Quality Improvement Program-Pediatric and the multicenter Pediatric Health Information System for patients with acute appendicitis. Comparisons for demographics, clinical outcomes, and hospital charges between children with impaired development versus neurotypical children were made using independent t test or Wilcoxon rank sum tests. The multivariable logistic regression model estimated the odds of complicated acute appendicitis in impaired development patients. Based on correlation analyses, hierarchical linear modeling was used to examine the extent to which impaired development influenced resource use.
RESULTS: Patients with impaired development were younger, had higher comorbidities, and were more commonly male sex. In the National Surgical Quality Improvement Program-Pediatric database, impaired development was associated with higher rates of complicated acute appendicitis (33.6% vs 27.5, P < .001), particularly in older children, and higher usage of computed tomography at National Surgical Quality Improvement Program-Pediatric hospitals (23.1% vs 15.1%, P < .001). In the Pediatric Health Information System database, the adjusted odds of complicated acute appendicitis were significantly higher in patients with impaired development (1.20 [1.09-1.31]), low childhood opportunity level (1.39 [95% confidence interval: 1.31-1.47]), and Black race (1.25 [1.17-1.33]). Hierarchical adjusted linear modeling showed that impaired development was associated with significantly higher hospital charges (9% increase).
CONCLUSION: Management of acute appendicitis in children with impaired development remains a challenge to clinicians, as evidenced by the higher rate of perforated appendicitis in older children, diagnostic computed tomography use at National Surgical Quality Improvement Program-Pediatric hospitals, postoperative computed tomography use, and increased costs.
FIELD: pharmaceutical industry. SUBSTANCE: invention relates to methods of preparing drugs with mineral filling agent, definite release type showing Bactericidal and wound-healing effect and used in veterinary science. Method involves preparing a mixture consisting of an active component and mineral filling agent. Mixing is carried out by crushing and grinding followed by use at solid state. Ready mixture is packaged into hermetic transparent crate (thickness is 1.5 cm) followed by irradiation by ultraviolet rays (wavelength is 10-300 nm) for 90 min, not less. An active component: a mixture of metal iodides and other mineral salts. Filling agent is chalk and components are used at the following mass ratio, mg/kg: iodine 18.0; copper 0.97; iron 5.12; manganese 1.12; zinc 0.05; cadmium 0.44; lead 8.25; water 35 x 10 6 , and chalk as a filling agent - the rest. EFFECT: enhanced effectiveness of preparation effect. 1 tbl, 3 ex
PURPOSE:To provide a gel-like massage agent excellent in its moisture effect, cleansing effect and blood circulation-promoting effect, and to provide the pack agent excellent in its skin obstruction effect. CONSTITUTION:The gel-like massage agent contains 20-90wt.% of glycerol, 1-10wt.% of a monoglycerol fatty acid ester, and 1-15wt.% of sucrose fatty acid ester, and a gel-like pack agent contains 20-95wt.% of a composition comprising 20-90wt.% of glycerol and 1-10wt.% of a monoglycerol fatty acid ester, 1-30wt.% of a sucrose fatty acid acid ester, and 1-10wt.% of a fatty acid an a higher alcohol. 30-98wt.% of the pack agent and 0.01-30wt.% of an emollient oil (e.g. olive oil, lanolin oil) and/or an oil soluble skin roughness-improving ingredient (e.g. vitamin A, gamma-oryzanol) are compounded with each other to provide the massage agent giving the same touch as that of a massage cream and simultaneously giving a warm heat touch when used for the massage. and capable of giving a skin obstruction touch when used for the pack.
Patients will be transferred from MDI to CSII with self-monitoring of blood glucose (SMBG) by endocrinologist-specialist in CSII or technical trainer individually and will be monitored by coaching specialist or local endocrinologist within 4 months prior to inclusion. All patients from this group should be educated about basic aspects of diabetes self-management at the School of Diabetes at least once earlier.
Intestinal ischemia reperfusion injury (II/R injury) is a common and intractable pathophysiological process in critical patients, for which exploring new treatments and mechanisms is of great importance to improve treatment outcomes. Apigenin-7-O-Glucoside (AGL) is a sugar derivative of apigenin natural product with various pharmacological activities to protect against intestinal diseases. In this study, we synthesized two amphiphilic molecules, namely DTPA-N10-10 and mPEG-TK-DA, which can scavenge free radicals and reactive oxygen species (ROS). They were successfully encapsulated AGL through self-assembly, resulting in the formation of multi-site ROS scavenging nanoparticles called PDN@AGL. In vitro and in vivo experiments demonstrated that PDN@AGL could protect intestinal tissues by reducing lipid peroxidation, lowering ROS levels and inhibiting ferroptosis during II/R injury. Furthermore, our study revealed, for the first time, that the regulation of the ATF3/SLC7A11 pathway by PDN@AGL may play a crucial role in mitigating II/R injury. In conclusion, our study confirmed the beneficial effects of PDN@AGL in combating II/R injury through the ATF3/SLC7A11-mediated regulation of ferroptosis and oxidative stress. These findings lay the groundwork for the potential application of PDN@AGL in the treatment of II/R injury.
Baculovirus vectors with improved ability to express transgenes are provided. The baculovirus vectors are genetically engineered to contain and express nucleic acid sequences that encode one or more proteins that interfere with mammalian host cell type I interferon (IFN) responses. Thus, the expression of transgenes encoded by the baculovirus vector is not inhibited by a type I DFN response, and the transgenes are freely expressed in mammalian host cells. Alternatively, baculovirus vectors with nucleotide sequences encoding one or more genes of interest (e.g. tuberculosis or malarial antigens) are co-administered with one or more proteins that interfere with mammalian host cell type I IFN responses; or with viral vectors (e.g. adenovectors) that express one or more proteins that interfere with mammalian host cell type I IFN responses.
OBJECTIVES: To examine if intergenerational transmission of parent weight talk occurs, the contextual factors prompting weight talk, and whether parent weight talk is associated with child weight, dietary intake, psychosocial outcomes, and food parenting practices.
STUDY DESIGN: Children aged 5-9 years and their families (n = 1307) from 6 racial and ethnic groups (African-American, Hispanic, Hmong, Native American, Somali/Ethiopian, White) were recruited for a longitudinal cohort study through primary care clinics in Minneapolis/St. Paul, Minnesota from 2016 through 2019. Parents filled out surveys at 2 time points, 18 months apart. Adjusted regression models examined associations of interest.
RESULTS: Intergenerational transmission of parent weight talk was observed. In addition, significant associations were found between parent engagement in weight talk and higher weight status and poorer psychosocial outcomes in children 18 months later. Parent engagement in weight talk was also associated with more restrictive food parenting practices 18 months later.
CONCLUSIONS: Parents' exposure to weight talk as children increased the likelihood of engaging in weight talk with their own children and had harmful associations over time with parent restrictive feeding practices, child weight, and psychosocial wellbeing in children. Health care providers may want to consider both modeling positive health-focused conversations and educating parents about the potential harmful and long-lasting consequences of engaging in weight talk with their children.
INTRODUCTION: Cancer-related fatigue (CRF) is one of the most common and painful symptoms in patients with prostate cancer (PCa). Moreover, PCa patients who receive the androgen deprivation therapy (ADT) are more likely to develop CRF. Baduanjin exercise has been shown to improve CRF in some cancers. However, such effects have not been verified in patients with PCa treated with the ADT. So, this study was designed as a randomised controlled trial (RCT) to explore the effects of Baduanjin exercise on CRF in PCa patients treated with the ADT.
METHODS AND ANALYSIS: This study will be a single-centre, assessor and statistician blinded, RCT consisting of a 12 week intervention and 12 week follow-up. Patients with PCa who meet the inclusion criteria will be recruited from Shanghai Hudong Hospital. Participants will be randomly assigned to Baduanjin exercise group (n=42) and the control group (n=42), performing 12 weeks of Baduanjin exercise or reeiving the standard care. The primary outcome will be the clinical effect of Baduanjin exercise on CRF in PCa patients, which will be measured using the Piper Fatigue Self-Assessment (PFS) scale, a multidimensional measure of CRF using three different dimensions: somatic, emotional and cognitive. The secondary outcome will be the clinical effect of the Baduanjin exercise on the patient's level of fatigue, sleep, depression and life quality at the time, which will be assessed by the Brief Fatigue Inventory (BFI), the Pittsburgh Sleep Quality Index (PSQI), the Beck Depression Inventory (BDI) and the Functional Assessment of Cancer Therapy-Prostate (FACT-P).
ETHICS AND DISSEMINATION: This study has been approved by Shanghai Hudong Hospital Ethics Committee, Shanghai province (2022 SHHDKY08). The trial results will be submitted to conferences and peer-reviewed journals.
TRAIL REGISTRATION NUMBER: ChiCTR2300074293.
Custom-built research muscle stimulator. Muscle stimulator is set to provide a comfortable stimulation when applied to the soleus muscle using two 5x5cm electrodes.
The invention discloses a Chinese stellera root tinea pedis ointment and a preparation method thereof. The ointment is composed of a main material and an auxiliary material; wherein the main material is composed of the following components by weight: 500 to 600 grams of Chinese stellera root, 60 to 70 grams of golden cypress, 50 to 60 grams of clove, 100 to 120 grams of gentian, 50 to 60 grams of radix astragali, 30 to 40 grams of sophora flavescens, and 40 to 50 grams of golden larch bark; and the auxiliary material is 900 to 1000 grams of white vaseline. The ointment is prepared by subjecting the raw materials mentioned above to steps of hot-extraction, condensation, spray-drying, and mixed preparation. The sterilization rate on fungus of the ointment is at least 20 times higher than that of normal western medicines. The ointment can kill the fungus in a short term, and generates a long term inhibiting effect. Patients can apply the ointment on the affected parts for 1 to 2 times a day, one complete treatment course lasts for continuous three days, the cure rate of tinea pedis can reach 98%, and the ointment has the advantages of short treatment course and difficult relapse and is an ideal drug for radically curing various kinds of beriberi and tinea pedis.
A system and method for monitoring the health of dialysis patients with Raman spectroscopy measurements of one or more target analytes is described. The methods include irradiating one or more fluids of interest with light to produce one or more spectrum and detecting the spectrum with a detector. The fluids of interest are preferably those related to dialysis, including hemodialysis and peritoneal dialysis. In a preferred embodiment, the fluids are irradiated with monochromatic light, and one or more Raman spectra are detected as a result of the irradiation. The fluids may be irradiated within the dialysis tubing itself, or removed from the dialysis tubing and irradiated in a separate chamber. The Raman spectra of one or more target analytes of a dialysis patient may be followed over time or compared to one or more reference spectra, thereby providing information on the health of dialysis patients.
BACKGROUND: Equine asthma (EA) is a chronic lower airway inflammation that leads to structural and functional changes. Hyaluronic acid (HA) has crucial functions in the extracellular matrix homeostasis and inflammatory mediator activity. HA concentration in the lungs increases in several human airway diseases. However, its associations with naturally occurring EA and airway remodelling have not been previously studied. Our aim was to investigate the association of equine neutrophilic airway inflammation (NAI) severity, airway remodelling, and HA concentration in horses with naturally occurring EA. We hypothesised that HA concentration and airway remodelling would increase with the severity of NAI. HA concentrations of bronchoalveolar lavage fluid supernatant (SUP) and plasma of 27 neutrophilic EA horses, and 28 control horses were measured. Additionally, remodelling and HA staining intensity were assessed from endobronchial biopsies from 10 moderate NAI horses, 5 severe NAI horses, and 15 control horses.
RESULTS: The HA concentration in SUP was higher in EA horses compared to controls (p = 0.007). Plasma HA concentrations were not different between the groups. In the endobronchial biopsies, moderate NAI horses showed epithelial hyperplasia and inflammatory cell infiltrate, while severe NAI horses also showed fibrosis and desquamation of the epithelium. The degree of remodelling was higher in severe NAI compared to moderate NAI (p = 0.048) and controls (p = 0.016). Intense HA staining was observed in bronchial cell membranes, basement membranes, and connective tissue without significant differences between the groups.
CONCLUSION: The release of HA to the airway lumen increases in naturally occurring neutrophilic EA without clear changes in its tissue distribution, and significant airway remodelling only develops in severe NAI.
No carcinogenicity studies were conducted with intravenous administration of amiodarone. However, oral amiodarone caused a statistically significant, dose-related increase in the incidence of thyroid tumors (follicular adenoma and carcinoma) in rats. The incidence of thyroid tumors in rats was greater than the incidence in controls even at the lowest dose level tested, i.e., 5 mg/kg/day (much less, on a body surface area basis, than the maximum recommended human maintenance dose of 600 mg/day).

Mutagenicity studies conducted with amiodarone HCl (Ames, micronucleus, and lysogenic induction tests) were negative.

No fertility studies were conducted with intravenous administration of amiodarone. However, in a study in which amiodarone HCl was orally administered to male and female rats, beginning 9 weeks prior to mating, reduced fertility was observed at a dose level of 90 mg/kg/day (approximately 1.4 times the maximum recommended human maintenance dose of 600 mg/day).
A treatment option has been proposed in the last decade, based on the change in understanding of carious biofilm development and caries progression. Sealing carious dentine beneath a restoration deprives the caries biofilm of nutrients and alters the environment sufficiently to slow or arrest lesion progression. This has the added benefit of avoiding pulp exposure and subsequent treatment (Santamaria, Innes, Machiulskiene, Evans, \& Splieth, 2014).

There is no clear evidence that leaving soft infected dentine, before sealing the cavity, is deleterious. Instead, this may prevent pulp exposure, preserve the pulp vitality, reduce the permeability of the remaining dentine by stimulating tertiary dentine formation, and so change the environment for the remaining microorganisms and thus arresting caries process. Silver diamine fluoride (SDF), Ag(NH3)2F, has been used to arrest caries since 1969.Silver Diamine Fluoride is a topical drug that is applied clinically to control active dental caries and prevent further progression of disease. Although, the ideal way to treat teeth with decay is removal of the decay and placing a restoration, this alternative treatment allows us to stop decay with non-invasive methods, especially with young children that have primary teeth. Treatment with Silver Diamine Fluoride does not eliminate the need for restorative dentistry to repair function or aesthetics, but has been effective at prevention of further decay.
PURPOSE:To prepare a hydrotalcite-coated powder excellent in the adsorption capacity, etc., and useful for an external skin preparation, deodorant, buccal compsn., etc., by coating the surfaces of particles of a power with a powder contg. hydrotalcite as the essential component. CONSTITUTION:A powder selected from the group consisting of nylon 6, polyethylene, polystyrene, polytetrafluoroethylene, aluminum sulfate, heavy magnesium carbonate, etc., is prepd. in advance. The surfaces of particles of the powder are coated with a powder of hydrotalcite or a mixture thereof with at least one other powder (e.g. bentonite) to give a hydrotalcite-coated powder. An example of the method for carrying out the coating is ball mill mixing. The coated powder is excellent in the adsorption capacity of skin egesta such as lower fatty acids and lipid peroxide, water absorbing and releasing properties, deodrizing effect, etc.
Thera Tears (Sodium Carboxymethylcellulose 0.25%) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).